Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Change in Accured Expenses (2019 - 2025)

AVITA Medical (RCEL) has disclosed Change in Accured Expenses for 5 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 156.3% year-over-year to $1.0 million, compared with a TTM value of $2.7 million through Dec 2025, up 707.35%, and an annual FY2025 reading of $2.7 million, up 707.35% over the prior year.
  • Change in Accured Expenses was $1.0 million for Q4 2025 at AVITA Medical, up from $806000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.7 million in Q4 2023 and bottomed at -$547000.0 in Q4 2022.
  • Average Change in Accured Expenses over 4 years is $351125.0, with a median of $149000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses tumbled 1680.0% in 2023, then skyrocketed 1126.61% in 2025.
  • Year by year, Change in Accured Expenses stood at -$547000.0 in 2022, then soared by 415.72% to $1.7 million in 2023, then tumbled by 76.55% to $405000.0 in 2024, then surged by 156.3% to $1.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RCEL at $1.0 million in Q4 2025, $806000.0 in Q3 2025, and -$218000.0 in Q2 2025.